Delhi: European Society for Medical Oncology (ESMO) in collaboration with EURACAN, the European Reference Network for rare adult solid cancers have released Clinical Practice Guideline for managing nasopharyngeal cancer (NPC).
Nasopharyngeal carcinoma is a disease with unique epidemiological features. The distribution of the disease demonstrates a clear regional, racial and gender prevalence. In general, the prognosis is better for women than men.
Key Recommendations
Diagnosis
- Definitive diagnosis is made by endoscopic-guided biopsy of the primary nasopharyngeal tumour ; diagnostic neck biopsy and/or neck nodal dissection should be avoided.
- Determination of EBV on the histological specimen by ISH is indicated.
- In regions where NPC is endemic, the use of plasma EBV DNA, coupled with endoscopic examination and MRI, can be recommended for detecting early, asymptomatic NPC.
Staging and risk assessment
- Routine staging procedures include medical history, physical examination with cranial nerve examination, CBC, serum biochemistry (including liver and renal function tests and LDH), nasopharyngoscopy and radiological imaging.
- MRI is the most accurate way of defining local and nodal tumour staging and it should be preferred whenever available and according to the centre's expertise.
- FDG-PET adds further accuracy in nodal staging, is the best imaging method for detecting distant metastases and is recommended at least in locally advanced disease.
- Baseline audiometric testing, dental examination, nutritional status evaluation, ophthalmological and endocrine evaluation should be performed as appropriate.
- Pre-treatment QoL scales may be suggested to better delineate the individual risk and to prompt medical or physical support before the start of treatment.
- Pre- and post-treatment plasma/serum load of EBV DNA has prognostic value.
Treatment
- The optimal treatment strategy for patients with advanced NPC should be discussed in an MDT. Patients should be treated at high-volume facilities.
- IMRT (Intensity-modulated radiotherapy)Intensity-modulated RT is the mainstay of treatment.
- Overall, RT is targeted according to the primary tumour, pathological nodes and adjacent regions considered at-risk of microscopic spread from the tumour, and generally to both sides of the neck (levels II-V and retropharyngeal nodes).
- A total dose of 70 Gy is needed for the eradication of macroscopic disease and 50-60 Gy for the treatment of potential at-risk sites.
- Planning optimisation in terms of prioritisation and dose constraints for target and radiosensitive structures is fundamental.
- Stage I-II disease is treated by RT alone; for stage II disease, this approach is only used when IMRT is adopted.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.